JP2017504314A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017504314A5 JP2017504314A5 JP2016539276A JP2016539276A JP2017504314A5 JP 2017504314 A5 JP2017504314 A5 JP 2017504314A5 JP 2016539276 A JP2016539276 A JP 2016539276A JP 2016539276 A JP2016539276 A JP 2016539276A JP 2017504314 A5 JP2017504314 A5 JP 2017504314A5
- Authority
- JP
- Japan
- Prior art keywords
- bispecific antibody
- domain
- amino acid
- acid sequence
- lymphoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090001123 antibodies Proteins 0.000 claims 46
- 102000004965 antibodies Human genes 0.000 claims 46
- 125000003275 alpha amino acid group Chemical group 0.000 claims 28
- 239000003814 drug Substances 0.000 claims 22
- 230000035772 mutation Effects 0.000 claims 13
- 210000004027 cells Anatomy 0.000 claims 12
- 230000003042 antagnostic Effects 0.000 claims 11
- 239000005557 antagonist Substances 0.000 claims 11
- 238000006467 substitution reaction Methods 0.000 claims 10
- 208000003950 B-Cell Lymphoma Diseases 0.000 claims 9
- 229920001184 polypeptide Polymers 0.000 claims 8
- 102100019764 PDCD1 Human genes 0.000 claims 7
- 108060007796 SPATA2 Proteins 0.000 claims 7
- 206010003816 Autoimmune disease Diseases 0.000 claims 4
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 claims 4
- 206010025310 Other lymphomas Diseases 0.000 claims 4
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims 4
- 230000002062 proliferating Effects 0.000 claims 4
- 208000009899 Burkitt Lymphoma Diseases 0.000 claims 3
- 206010025323 Lymphomas Diseases 0.000 claims 3
- 208000002098 Purpura, Thrombocytopenic, Idiopathic Diseases 0.000 claims 3
- 206010047802 Waldenstrom's macroglobulinaemias Diseases 0.000 claims 3
- 201000003444 follicular lymphoma Diseases 0.000 claims 3
- 201000008064 heavy chain disease Diseases 0.000 claims 3
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 claims 3
- 206010000880 Acute myeloid leukaemia Diseases 0.000 claims 2
- 102100007290 CD274 Human genes 0.000 claims 2
- 101710012053 CD274 Proteins 0.000 claims 2
- 206010007953 Central nervous system lymphoma Diseases 0.000 claims 2
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 claims 2
- 206010012818 Diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 2
- 102000004851 Immunoglobulin G Human genes 0.000 claims 2
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 claims 2
- 241000282567 Macaca fascicularis Species 0.000 claims 2
- 206010026798 Mantle cell lymphomas Diseases 0.000 claims 2
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 claims 2
- 102100007289 PDCD1LG2 Human genes 0.000 claims 2
- 101710011976 PDCD1LG2 Proteins 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 239000000611 antibody drug conjugate Substances 0.000 claims 2
- 108091008116 antibody drug conjugates Proteins 0.000 claims 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 2
- 230000002708 enhancing Effects 0.000 claims 2
- 201000009277 hairy cell leukemia Diseases 0.000 claims 2
- 230000036737 immune function Effects 0.000 claims 2
- 201000009251 multiple myeloma Diseases 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 206010002412 Angiocentric lymphomas Diseases 0.000 claims 1
- 108010047814 Antigen-Antibody Complex Proteins 0.000 claims 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 claims 1
- 208000004736 B-Cell Leukemia Diseases 0.000 claims 1
- 206010073480 B-cell prolymphocytic leukaemia Diseases 0.000 claims 1
- 108010071919 Bispecific Antibodies Proteins 0.000 claims 1
- 210000000988 Bone and Bones Anatomy 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 210000003169 Central Nervous System Anatomy 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010012601 Diabetes mellitus Diseases 0.000 claims 1
- 206010061850 Extranodal marginal zone B-cell lymphoma (MALT type) Diseases 0.000 claims 1
- 210000001280 Germinal Center Anatomy 0.000 claims 1
- 208000005017 Glioblastoma Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000005209 Hematologic Disease Diseases 0.000 claims 1
- 206010020243 Hodgkin's disease Diseases 0.000 claims 1
- 201000006743 Hodgkin's lymphoma Diseases 0.000 claims 1
- 208000010159 IGA Glomerulonephritis Diseases 0.000 claims 1
- 206010021263 IgA nephropathy Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010021972 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 208000001152 Leukemia, Prolymphocytic, B-Cell Diseases 0.000 claims 1
- 210000003563 Lymphoid Tissue Anatomy 0.000 claims 1
- 208000006557 Lymphoma, B-Cell, Marginal Zone Diseases 0.000 claims 1
- 208000006116 Lymphomatoid Granulomatosis Diseases 0.000 claims 1
- 201000003791 MALT lymphoma Diseases 0.000 claims 1
- 102100000165 MS4A1 Human genes 0.000 claims 1
- 101710010909 MS4A1 Proteins 0.000 claims 1
- 206010025650 Malignant melanoma Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 206010028417 Myasthenia gravis Diseases 0.000 claims 1
- 210000003928 Nasal Cavity Anatomy 0.000 claims 1
- 206010029331 Neuropathy peripheral Diseases 0.000 claims 1
- 108010019706 Nivolumab Proteins 0.000 claims 1
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims 1
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 229950010773 Pidilizumab Drugs 0.000 claims 1
- 208000007525 Plasmablastic Lymphoma Diseases 0.000 claims 1
- 208000007452 Plasmacytoma Diseases 0.000 claims 1
- 206010036105 Polyneuropathy Diseases 0.000 claims 1
- 208000004358 Polyneuropathy Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000003782 Raynaud Disease Diseases 0.000 claims 1
- 206010037912 Raynaud's phenomenon Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims 1
- 108010001645 Rituximab Proteins 0.000 claims 1
- 206010040767 Sjogren's syndrome Diseases 0.000 claims 1
- 210000000278 Spinal Cord Anatomy 0.000 claims 1
- 206010062113 Splenic marginal zone lymphoma Diseases 0.000 claims 1
- 206010043561 Thrombocytopenic purpura Diseases 0.000 claims 1
- 210000001541 Thymus Gland Anatomy 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 108091006028 chimera Proteins 0.000 claims 1
- 230000001684 chronic Effects 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- 201000006569 extramedullary plasmacytoma Diseases 0.000 claims 1
- 230000003325 follicular Effects 0.000 claims 1
- 201000008052 gamma heavy chain disease Diseases 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 201000002138 hematopoietic system disease Diseases 0.000 claims 1
- 238000002513 implantation Methods 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 108010045030 monoclonal antibodies Proteins 0.000 claims 1
- 102000005614 monoclonal antibodies Human genes 0.000 claims 1
- 210000004877 mucosa Anatomy 0.000 claims 1
- 201000001069 multicentric Castleman disease Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 229960003301 nivolumab Drugs 0.000 claims 1
- 201000006039 nodal marginal zone lymphoma Diseases 0.000 claims 1
- 229960003347 obinutuzumab Drugs 0.000 claims 1
- 108010045555 obinutuzumab Proteins 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 108010051812 pidilizumab Proteins 0.000 claims 1
- 201000004681 psoriasis Diseases 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 230000003393 splenic Effects 0.000 claims 1
- 201000007023 thrombotic thrombocytopenic purpura Diseases 0.000 claims 1
Claims (45)
- 二特異性抗体であって、次の6つのHVR:
(a)配列番号1のアミノ酸配列を含むHVR−H1、
(b)配列番号2のアミノ酸配列を含むHVR−H2、
(c)配列番号3のアミノ酸配列を含むHVR−H3、
(d)配列番号4のアミノ酸配列を含むHVR−L1、
(e)配列番号5のアミノ酸配列を含むHVR−L2、および
(f)配列番号6のアミノ酸配列を含むHVR−L3
を含む第1結合ドメインを含む抗CD3アーム、ならびに
次の6つのHVR:
(a)配列番号157のアミノ酸配列を含むHVR−H1、
(b)配列番号158のアミノ酸配列を含むHVR−H2、
(c)配列番号159のアミノ酸配列を含むHVR−H3、
(d)配列番号160のアミノ酸配列を含むHVR−L1、
(e)配列番号161のアミノ酸配列を含むHVR−L2、および
(f)配列番号162のアミノ酸配列を含むHVR−L3
を含む第2結合ドメインを含む抗CD20アーム
を含む、二特異性抗体。 - 前記第1結合ドメインが(a)配列番号184のアミノ酸配列に対して少なくとも95%の配列同一性を有するアミノ酸配列を含む重鎖可変(VH)ドメイン、(b)配列番号185のアミノ酸配列に対して少なくとも95%の配列同一性を有するアミノ酸配列を含む軽鎖可変(VL)ドメイン、または(c)(a)のとおりのVHドメインと(b)のとおりのVLドメインを含む、請求項1に記載の二特異性抗体。
- 前記VHドメインが配列番号184のアミノ酸配列を含む、及び/又は
前記VLドメインが配列番号185のアミノ酸配列を含む、請求項2に記載の二特異性抗体。 - 前記第2結合ドメインが(a)配列番号266のアミノ酸配列に対して少なくとも95%の配列同一性を有するアミノ酸配列を含むVHドメイン、(b)配列番号267のアミノ酸配列に対して少なくとも95%の配列同一性を有するアミノ酸配列を含むVLドメイン、または(c)(a)のとおりのVHドメインと(b)のとおりのVLドメインを含む、請求項1から3のいずれか一項に記載の二特異性抗体。
- (a)前記VHドメインが配列番号266のアミノ酸配列を含む、及び/又は(b)前記VLドメインが配列番号267のアミノ酸配列を含む、請求項4に記載の二特異性抗体。
- 二特異性抗体は、(a)配列番号184のアミノ酸配列を含むVHドメインと(b)配列番号185のアミノ酸配列を含むVLドメインを含む第1結合ドメインを含む抗CD3アーム、および(a)配列番号266のアミノ酸配列を含むVHドメインと(b)配列番号267のアミノ酸配列を含むVLドメインを含む第2結合ドメインを含む抗CD20アームを含む、請求項1から5のいずれか一項に記載の二特異性抗体。
- 前記第1結合ドメインがヒトCD3ポリペプチドまたはカニクイザル(cyno)CD3ポリペプチドに結合する、請求項1から請求項6のいずれか一項に記載の二特異性抗体。
- (a)前記ヒトCD3ポリペプチドは、ヒトCD3εポリペプチドまたはヒトCD3γポリペプチドである、あるいは(b)カニクイザルCD3ポリペプチドは、カニクイザルCD3εポリペプチドまたはカニクイザルCD3γポリペプチドである、請求項7に記載の二特異性抗体。
- 前記二特異性抗体が非グリコシル化部位突然変異を含む、請求項1から請求項8のいずれか一項に記載の二特異性抗体。
- 前記非グリコシル化部位突然変異によって前記二特異性抗体のエフェクター機能が低下する、請求項9に記載の二特異性抗体。
- 前記非グリコシル化部位突然変異が置換突然変異である、請求項9または10に記載の二特異性抗体。
- 前記二特異性抗体が、エフェクター機能を低下させる、Fc領域中の置換突然変異を含む、請求項1から請求項11のいずれか一項に記載の二特異性抗体。
- 前記置換突然変異がアミノ酸残基N297、L234、L235、および/またはD265(EU付番)にある、請求項11または請求項12に記載の二特異性抗体。
- 前記置換突然変異がN297G、N297A、L234A、L235A、およびD265Aからなる群より選択される、請求項13に記載の二特異性抗体。
- 前記二特異性抗体が
(i)モノクローナル抗体、ヒト抗体、ヒト化抗体、またはキメラ抗体である、
(ii)完全長抗体である、および/または
(iii)IgG抗体である、
請求項1から請求項14のいずれか一項に記載の二特異性抗体。 - (a)前記抗CD3アームがT366S置換突然変異、L368A置換突然変異、Y407V置換突然変異、およびN297G置換突然変異を含み、且つ、(b)前記抗CD20アームがT366W置換突然変異およびN297G置換突然変異を含む、請求項1から15のいずれか一項に記載の二特異性抗体。
- 前記二特異性抗体が1つ以上の重鎖定常ドメインを含み、前記1つ以上の重鎖定常ドメインが第1のCH1(CH11)ドメイン、第1のCH2(CH21)ドメイン、第1のCH3(CH31)ドメイン、第2のCH1(CH12)ドメイン、第2のCH2(CH22)ドメイン、および第2のCH3(CH32)ドメインから選択される、請求項1から請求項16のいずれか一項に記載の二特異性抗体。
- 前記1つ以上の重鎖定常ドメインのうちの少なくとも1つが別の重鎖定常ドメインと対になり:
(i)前記CH31ドメインと前記CH32ドメインがそれぞれ出っ張りまたは窪みを含み、前記CH31ドメイン中の出っ張りまたは窪みがそれぞれ前記CH32ドメイン中の窪みまたは出っ張りに位置することができる;または(ii)前記CH21ドメインと前記CH22ドメインがそれぞれ出っ張りまたは窪みを含み、前記CH21ドメイン中の出っ張りまたは窪みがそれぞれ前記CH22ドメイン中の窪みまたは出っ張りに位置することができる、
請求項17に記載の二特異性抗体。 - 請求項1から請求項18のいずれか一項に記載の二特異性抗体をコードする単離核酸。
- 請求項19に記載の単離核酸を含むベクター。
- 請求項20に記載のベクターを含む宿主細胞。
- 請求項1から請求項18のいずれか一項に記載の二特異性抗体の作製方法であって、培地中で請求項21に記載の宿主細胞を培養することおよび前記宿主細胞または前記培地から前記二特異性抗体を回収することを含む、方法。
- 請求項1から請求項18のいずれか一項に記載の二特異性抗体および細胞傷害剤を含む、免疫複合体。
- 請求項1から請求項18のいずれか一項に記載の二特異性抗体、および薬学的に許容可能な担体、賦形剤または希釈剤を含む組成物。
- 前記組成物がPD−1軸結合性アンタゴニストまたは追加の治療剤をさらに含む、請求項24に記載の組成物。
- 請求項1から請求項18のいずれか一項に記載の二特異性抗体を含む、それを必要とする対象における、細胞増殖性疾患の治療、またはその進行の遅延化のための、医薬。
- 請求項1から請求項18のいずれか一項に記載の二特異性抗体を含む、細胞増殖性疾患を有する対象における免疫機能の強化のための医薬。
- 前記細胞増殖性疾患が、乳癌、大腸癌、非小細胞性肺癌、非ホジキンリンパ腫(NHL)、B細胞リンパ腫、B細胞性白血病、多発性骨髄腫、腎臓癌、前立腺癌、肝臓癌、頭頸部癌、黒色腫、卵巣癌、中皮腫、膠芽腫、胚中心B細胞様(GCB)DLBCL、活性化B細胞様(ABC)DLBCL、濾胞性リンパ腫(FL)、マントル細胞リンパ腫(MCL)、急性骨髄性白血病(AML)、慢性リンパ性白血病(CLL)、辺縁帯リンパ腫(MZL)、小リンパ球性リンパ腫(SLL)、リンパ形質細胞性リンパ腫(LL)、ワルデンストレームマクログロブリン血症(WM)、中枢神経系リンパ腫(CNSL)、バーキットリンパ腫(BL)、B細胞性前リンパ球性白血病、脾臓周辺帯リンパ腫、有毛状細胞性白血病、脾リンパ腫/脾性白血病分類不能型、びまん性赤脾髄小型B細胞リンパ腫、有毛状細胞性白血病亜型、ワルデンストレームマクログロブリン血症、重鎖病、α重鎖病、γ重鎖病、μ重鎖病、形質細胞性骨髄腫、孤発性骨形質細胞腫、骨外性形質細胞腫、粘膜関連リンパ組織型節外性辺縁帯リンパ腫(MALTリンパ腫)、節性辺縁帯リンパ腫、小児節性辺縁帯リンパ腫、小児濾胞性リンパ腫、原発性皮膚濾胞中心リンパ腫、T細胞/組織球豊富型大細胞型B細胞リンパ腫、中枢神経原発性DLBCL、皮膚原発性DLBCL下肢型、高齢者EBV陽性DLBCL、慢性炎症付随型DLBCL、リンパ腫様肉芽腫症、縦隔(胸腺)原発性大細胞型B細胞リンパ腫、血管内大細胞型B細胞リンパ腫、ALK陽性大細胞型B細胞リンパ腫、形質芽球性リンパ腫、HHV8関連多中心性キャッスルマン病に生ずる大細胞型B細胞リンパ腫、びまん性大細胞型B細胞リンパ腫とバーキットリンパ腫の中間の特徴を有する原発性滲出性リンパ腫/B細胞リンパ腫分類不能型、およびびまん性大細胞型B細胞リンパ腫と古典的ホジキンリンパ腫の中間の特徴を有するB細胞リンパ腫分類不能型からなる群より選択される癌である、請求項26または27に記載の医薬。
- 請求項1から請求項18のいずれか一項に記載の二特異性抗体を含む、それを必要とする対象における、自己免疫疾患の治療、またはその進行の遅延化のための医薬。
- 請求項1から請求項18のいずれか一項に記載の二特異性抗体を含む、自己免疫疾患を有する対象における免疫機能の強化のための医薬。
- 前記自己免疫疾患がリウマチ性関節炎、若年性リウマチ性関節炎、全身性エリテマトーデス(SLE)、ウェゲナー病、炎症性腸疾患、特発性血小板減少性紫斑病(ITP)、血栓性血小板減少性紫斑病(TTP)、自己免疫性血小板減少症、多発性硬化症、乾癬、IgA腎症、IgM多発ニューロパシー、重症筋無力症、脈管炎、糖尿病、レイノー症候群、シェーングレン症候群、糸球体腎炎、視神経脊髄炎(NMO)およびIgGニューロパシーからなる群より選択される、請求項29または請求項30に記載の医薬。
- 二特異性抗体が(a)免疫エフェクター細胞上に位置するCD3分子および(b)前記免疫エフェクター細胞以外の標的細胞上に位置するCD20分子に結合する、請求項1から請求項18のいずれか一項に記載の二特異性抗体を含む、医薬。
- 前記二特異性抗体が(a)および(b)に結合した後に前記免疫エフェクター細胞を活性化する、請求項32に記載の医薬。
- 前記二特異性抗体が約0.01mg/kgから約10mg/kg、約0.1mg/kgから約10mg/kg、または約1mg/kgの投与量で前記対象に投与されるために製剤化される、請求項26から請求項33のいずれか一項に記載の医薬。
- 二特異性抗体が、PD−1軸結合性アンタゴニストおよび/または追加の治療薬と組み合わせて前記対象に投与するために製剤化される、請求項26から請求項34のいずれか一項に記載の医薬。
- 前記PD−1軸結合性アンタゴニストがPD−L1結合性アンタゴニストである、請求項35に記載の医薬。
- 前記PD−L1結合性アンタゴニストがYW243.55.S70、MPDL3280A、MDX−1105、およびMEDI4736からなる群より選択される、請求項36に記載の医薬。
- 前記PD−1軸結合性アンタゴニストがPD−1結合性アンタゴニストである、請求項35に記載の医薬。
- 前記PD−1結合性アンタゴニストがMDX−1106(ニボルマブ)、MK−3475(ランブロリズマブ)、CT−011(ピディリズマブ)、およびAMP−224からなる群より選択される、請求項38に記載の医薬。
- 前記PD−1軸結合性アンタゴニストがPD−L2結合性アンタゴニストである、請求項35に記載の医薬。
- 前記PD−L2結合性アンタゴニストが抗体またはイムノアドヘンシンである、請求項40に記載の医薬。
- 前記二特異性抗体が、グルココルチコイド、リツキシマブ、オビヌツズマブまたは抗体薬物複合体(ADC)と組み合わせて使用するために製剤化される、請求項26から請求項41のいずれか一項に記載の医薬。
- 前記二特異性抗体が皮下に、静脈内に、筋肉内に、局所に、経口で、経皮で、腹腔内に、眼窩内に、移植によって、吸入によって、髄腔内に、脳室内に、または鼻腔内に投与されるために製剤化される、請求項26から請求項42のいずれか一項に記載の医薬。
- 前記対象がヒトである、請求項26から請求項43のいずれか一項に記載の医薬。
- (a)請求項24または請求項25に記載の組成物、および
(b)前記組成物を対象に投与し、細胞増殖性疾患または自己免疫疾患を治療するため、またはその進行を遅延化するための指示を含むパッケージ挿入物
を含むキット。
Applications Claiming Priority (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361917346P | 2013-12-17 | 2013-12-17 | |
US61/917,346 | 2013-12-17 | ||
US201461949950P | 2014-03-07 | 2014-03-07 | |
US61/949,950 | 2014-03-07 | ||
US201462026594P | 2014-07-18 | 2014-07-18 | |
US62/026,594 | 2014-07-18 | ||
US201462053582P | 2014-09-22 | 2014-09-22 | |
US62/053,582 | 2014-09-22 | ||
US201462091441P | 2014-12-12 | 2014-12-12 | |
US62/091,441 | 2014-12-12 | ||
PCT/US2014/070951 WO2015095392A1 (en) | 2013-12-17 | 2014-12-17 | Anti-cd3 antibodies and methods of use |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017221759A Division JP6526158B2 (ja) | 2013-12-17 | 2017-11-17 | 抗cd3抗体および使用方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2017504314A JP2017504314A (ja) | 2017-02-09 |
JP2017504314A5 true JP2017504314A5 (ja) | 2018-01-18 |
JP6449295B2 JP6449295B2 (ja) | 2019-01-09 |
Family
ID=52394341
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016539276A Active JP6449295B2 (ja) | 2013-12-17 | 2014-12-17 | 抗cd3抗体および使用方法 |
JP2017221759A Active JP6526158B2 (ja) | 2013-12-17 | 2017-11-17 | 抗cd3抗体および使用方法 |
JP2019044073A Active JP6764968B2 (ja) | 2013-12-17 | 2019-03-11 | 抗cd3抗体および使用方法 |
JP2020153481A Withdrawn JP2021006042A (ja) | 2013-12-17 | 2020-09-14 | 抗cd3抗体および使用方法 |
JP2022098882A Active JP7418501B2 (ja) | 2013-12-17 | 2022-06-20 | 抗cd3抗体および使用方法 |
JP2022098883A Withdrawn JP2022137074A (ja) | 2013-12-17 | 2022-06-20 | 抗cd3抗体および使用方法 |
Family Applications After (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017221759A Active JP6526158B2 (ja) | 2013-12-17 | 2017-11-17 | 抗cd3抗体および使用方法 |
JP2019044073A Active JP6764968B2 (ja) | 2013-12-17 | 2019-03-11 | 抗cd3抗体および使用方法 |
JP2020153481A Withdrawn JP2021006042A (ja) | 2013-12-17 | 2020-09-14 | 抗cd3抗体および使用方法 |
JP2022098882A Active JP7418501B2 (ja) | 2013-12-17 | 2022-06-20 | 抗cd3抗体および使用方法 |
JP2022098883A Withdrawn JP2022137074A (ja) | 2013-12-17 | 2022-06-20 | 抗cd3抗体および使用方法 |
Country Status (33)
Country | Link |
---|---|
US (7) | US10174124B2 (ja) |
EP (4) | EP4410315A2 (ja) |
JP (6) | JP6449295B2 (ja) |
KR (5) | KR102433591B1 (ja) |
CN (4) | CN116041529A (ja) |
AU (3) | AU2014364805B2 (ja) |
BR (3) | BR122021025087B1 (ja) |
CA (3) | CA3131724A1 (ja) |
CL (1) | CL2016001556A1 (ja) |
CR (1) | CR20160314A (ja) |
DK (3) | DK3192812T3 (ja) |
EA (1) | EA038933B1 (ja) |
ES (2) | ES2813074T3 (ja) |
FI (1) | FI3736292T3 (ja) |
FR (1) | FR22C1048I2 (ja) |
HR (2) | HRP20201143T1 (ja) |
HU (3) | HUE050159T2 (ja) |
IL (3) | IL263466B2 (ja) |
LT (4) | LT3736292T (ja) |
MX (2) | MX2016007958A (ja) |
NL (1) | NL301194I2 (ja) |
NZ (1) | NZ721309A (ja) |
PE (3) | PE20161217A1 (ja) |
PH (1) | PH12016501186A1 (ja) |
PL (2) | PL3192812T3 (ja) |
PT (3) | PT3192812T (ja) |
RS (2) | RS60443B1 (ja) |
SG (3) | SG10201809385RA (ja) |
SI (2) | SI3192812T1 (ja) |
TW (3) | TWI643873B (ja) |
UA (1) | UA120753C2 (ja) |
WO (1) | WO2015095392A1 (ja) |
ZA (2) | ZA201603755B (ja) |
Families Citing this family (226)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112013013311A2 (pt) | 2010-11-30 | 2017-09-19 | Chugai Pharmaceutical Co Ltd | agente terapêutico de indução de citotoxicidade |
CA2844540C (en) | 2011-08-23 | 2018-10-16 | Roche Glycart Ag | Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use |
US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
MY181648A (en) | 2012-08-24 | 2020-12-30 | Univ California | Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis |
JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
KR20150064068A (ko) | 2012-10-08 | 2015-06-10 | 로슈 글리카트 아게 | 2개의 Fab 단편을 포함하는 FC-부재 항체 및 이용 방법 |
US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
DK2943511T3 (da) | 2013-01-14 | 2019-10-21 | Xencor Inc | Nye heterodimeriske proteiner |
US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
CA2896370A1 (en) | 2013-02-26 | 2014-09-04 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
EP3708584A1 (en) | 2013-02-26 | 2020-09-16 | Roche Glycart AG | Bispecific t cell activating antigen binding molecules |
CN105121465B (zh) | 2013-03-13 | 2020-09-08 | 普罗塞纳生物科技公司 | Tau免疫疗法 |
WO2014153164A1 (en) | 2013-03-14 | 2014-09-25 | The California Institute For Biomedical Research | Targeting agent antibody conjugates and uses thereof |
US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
DK2970486T3 (en) | 2013-03-15 | 2018-08-06 | Xencor Inc | MODULATION OF T-CELLS WITH BISPECIFIC ANTIBODIES AND FC-FUSIONS |
US10519242B2 (en) | 2013-03-15 | 2019-12-31 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
TWI654206B (zh) | 2013-03-16 | 2019-03-21 | 諾華公司 | 使用人類化抗-cd19嵌合抗原受體治療癌症 |
AR096687A1 (es) | 2013-06-24 | 2016-01-27 | Genentech Inc | Anticuerpos anti-fcrh5 |
IL290613B1 (en) | 2013-07-05 | 2024-07-01 | Genmab As | CD3 antibodies of human origin or chimeras |
CA3131724A1 (en) | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
MX2016008098A (es) | 2013-12-20 | 2017-01-11 | Hoffmann La Roche | Anticuerpos biespecificos del receptor 2 de factor de crecimiento ipidermico himano (her2) y metodo de uso. |
TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗pd-l1之人類抗體 |
TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對pd-1的人類抗體 |
US10618963B2 (en) | 2014-03-12 | 2020-04-14 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
US9394365B1 (en) | 2014-03-12 | 2016-07-19 | Yeda Research And Development Co., Ltd | Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease |
US10519237B2 (en) | 2014-03-12 | 2019-12-31 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
AU2015228372B2 (en) | 2014-03-12 | 2018-05-31 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
TWI701042B (zh) * | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
JP2017510577A (ja) * | 2014-03-26 | 2017-04-13 | フラウンホーファ−ゲゼルシャフト ツァー フォルデルング デア アンゲバンデン フォルシュンク エー. ファオ.Fraunhofer−Gesellschaft Zur Forderung Der Angewandten Forschung E. V. | 抗TNF−α抗体療法の賦活剤としてのCD64ブロック剤の使用法 |
BR112016022385A2 (pt) | 2014-03-28 | 2018-06-19 | Xencor, Inc | anticorpos específicos que se ligam a cd38 e cd3 |
MX2016012552A (es) | 2014-04-07 | 2017-01-09 | Chugai Pharmaceutical Co Ltd | Molecula ligada a antigeno inmunoactivada. |
IL307423A (en) * | 2014-04-07 | 2023-12-01 | Novartis Ag | Cancer treatment using chimeric antigen receptor (CAR) against CD19 |
BR112016026299A2 (ja) | 2014-05-13 | 2018-02-20 | Chugai Seiyaku Kabushiki Kaisha | The T-lymph cell redirection antigen joint molecule to the cell which has an immunosuppressive function |
EP3195168B1 (en) * | 2014-07-31 | 2022-09-07 | The University Of Western Australia | A method for the identification of immunotherapy-drug combinations using a network approach |
BR112016030462A2 (pt) | 2014-08-04 | 2018-01-16 | F. Hoffmann-La Roche Ag | moléculas de ligação, um ou mais polinucleotídeos isolados, um ou mais vetores, célula hospedeira, método de produção de uma molécula de ligação, composição farmacêutica, uso da molécula de ligação, método de tratamento de doenças e de indução da lise de células alvo |
WO2016019969A1 (en) | 2014-08-08 | 2016-02-11 | Ludwig-Maximilians-Universität München | Subcutaneously administered bispecific antibodies for use in the treatment of cancer |
AR101846A1 (es) | 2014-09-12 | 2017-01-18 | Genentech Inc | Anticuerpos anti-cll-1 e inmunoconjugados |
US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
KR102614189B1 (ko) * | 2014-11-17 | 2023-12-18 | 리제너론 파아마슈티컬스, 인크. | Cd3xcd20 이특이적 항체를 이용한 종양의 치료 방법 |
WO2016079050A1 (en) | 2014-11-20 | 2016-05-26 | F. Hoffmann-La Roche Ag | Combination therapy of t cell activating bispecific antigen binding molecules cd3 abd folate receptor 1 (folr1) and pd-1 axis binding antagonists |
TN2017000222A1 (en) | 2014-11-26 | 2018-10-19 | Xencor Inc | Heterodimeric antibodies that bind cd3 and cd38 |
AU2015353409B2 (en) | 2014-11-26 | 2019-05-09 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
EA201790984A1 (ru) * | 2014-12-05 | 2018-05-31 | Дженентек, Инк. | Анти-cd79b антитела и способы их применения |
US10428155B2 (en) | 2014-12-22 | 2019-10-01 | Xencor, Inc. | Trispecific antibodies |
MX2017008875A (es) * | 2015-01-08 | 2017-09-27 | Genmab As | Anticuerpos biespecificos contra cd3 y cd20. |
US10227411B2 (en) | 2015-03-05 | 2019-03-12 | Xencor, Inc. | Modulation of T cells with bispecific antibodies and FC fusions |
CA2981312C (en) | 2015-03-30 | 2023-09-26 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to fc gamma receptors |
BR112017021500A2 (pt) | 2015-04-08 | 2018-09-25 | Novartis Ag | terapias com cd20, terapias com cd22 e terapias de combinação com uma célula que expressa (car) receptor de antígeno quimérico de cd19 |
CN114773476A (zh) * | 2015-04-13 | 2022-07-22 | 辉瑞公司 | 治疗性抗体和它们的用途 |
EP3778640A1 (en) | 2015-05-01 | 2021-02-17 | Genentech, Inc. | Masked anti-cd3 antibodies and methods of use |
AR105026A1 (es) | 2015-06-16 | 2017-08-30 | Genentech Inc | ANTICUERPOS MADURADOS POR AFINIDAD Y HUMANIZADOS PARA FcRH5 Y MÉTODOS PARA SU USO |
US10501545B2 (en) | 2015-06-16 | 2019-12-10 | Genentech, Inc. | Anti-CLL-1 antibodies and methods of use |
EP3310811B1 (en) | 2015-06-16 | 2021-06-16 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
CA2986592A1 (en) | 2015-06-17 | 2016-12-22 | Genentech, Inc. | Anti-her2 antibodies and methods of use |
WO2016207240A1 (en) | 2015-06-24 | 2016-12-29 | F. Hoffmann-La Roche Ag | Anti-transferrin receptor antibodies with tailored affinity |
EP3320773B9 (en) * | 2015-07-10 | 2023-10-11 | Chugai Seiyaku Kabushiki Kaisha | Mouse having human cd3 gene substituted for endogenous cd3 gene |
MX2018000621A (es) | 2015-07-13 | 2018-05-11 | Cytomx Therapeutics Inc | Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y metodos de uso de los mismos. |
TWI744242B (zh) | 2015-07-31 | 2021-11-01 | 德商安美基研究(慕尼黑)公司 | Egfrviii及cd3抗體構築體 |
TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究(慕尼黑)公司 | Msln及cd3抗體構築體 |
TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究(慕尼黑)公司 | Flt3及cd3抗體構築體 |
TWI717375B (zh) | 2015-07-31 | 2021-02-01 | 德商安美基研究(慕尼黑)公司 | Cd70及cd3抗體構築體 |
AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
JP6657392B2 (ja) | 2015-10-02 | 2020-03-04 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 二重特異性抗ヒトcd20/ヒトトランスフェリン受容体抗体及び使用方法 |
CA2990755A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffman-La Roche Ag | Bispecific anti-ceaxcd3 t cell activating antigen binding molecules |
US11660340B2 (en) | 2015-11-18 | 2023-05-30 | Chugai Seiyaku Kabushiki Kaisha | Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function |
EP3378488A4 (en) * | 2015-11-18 | 2019-10-30 | Chugai Seiyaku Kabushiki Kaisha | METHOD FOR ENHANCING THE HUMORAL IMMUNE RESPONSE |
CA3007030A1 (en) | 2015-12-07 | 2017-06-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and psma |
CA2997406C (en) | 2015-12-09 | 2024-05-28 | F. Hoffmann-La Roche Ag | Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies or cytokine release |
JP6955507B2 (ja) | 2015-12-14 | 2021-10-27 | マクロジェニクス,インコーポレーテッド | Pd‐1及びctla‐4との免疫応答性を有する二重特異性並びにその使用方法 |
RS64588B1 (sr) * | 2015-12-22 | 2023-10-31 | Regeneron Pharma | Kombinacija anti-pd-1 antitela i bispecifičnih anti-cd20/anti-cd3 antitela za lečenje kancera |
AU2017205089B2 (en) | 2016-01-08 | 2023-10-05 | F. Hoffmann-La Roche Ag | Methods of treating CEA-positive cancers using PD-1 axis binding antagonists and anti-CEA/anti-CD3 bispecific antibodies |
KR20180127966A (ko) * | 2016-01-09 | 2018-11-30 | 아르벨 리미티드 | 암 치료를 위한 카드헤린-17 특이적 항체 및 세포독성 세포 |
EA039859B1 (ru) | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
CA3013463C (en) | 2016-02-04 | 2024-05-21 | The California Institute For Biomedical Research | Humanized anti-cd3 antibodies, conjugates and uses thereof |
CA3014934A1 (en) | 2016-03-04 | 2017-09-08 | JN Biosciences, LLC | Antibodies to tigit |
PE20231511A1 (es) | 2016-03-22 | 2023-09-26 | Hoffmann La Roche | Moleculas biespecificas de celulas t activadas por proteasas que se unen especificamente al receptor 1 de folato (folr1) y cd3 |
KR102471787B1 (ko) | 2016-05-02 | 2022-11-29 | 프로테나 바이오사이언시즈 리미티드 | 타우 인식 항체 |
BR112018072394A2 (pt) | 2016-05-02 | 2019-02-19 | Prothena Biosciences Limited | anticorpos que reconhecem a tau |
PT3452507T (pt) | 2016-05-02 | 2022-12-20 | Prothena Biosciences Ltd | Imunoterapia anti-tau |
TWI822521B (zh) | 2016-05-13 | 2023-11-11 | 美商再生元醫藥公司 | 藉由投予pd-1抑制劑治療皮膚癌之方法 |
EP3252078A1 (en) | 2016-06-02 | 2017-12-06 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
AU2017278325A1 (en) * | 2016-06-07 | 2019-01-24 | Macrogenics, Inc. | Combination therapy |
IL263542B1 (en) | 2016-06-14 | 2024-06-01 | Xencor Inc | Bispecific antibodies inhibit immunological checkpoint |
AU2017281830B2 (en) | 2016-06-20 | 2023-04-06 | Kymab Limited | Anti-PD-L1 antibodies |
WO2018005519A2 (en) | 2016-06-27 | 2018-01-04 | The Regents Of The University Of California | Cancer treatment combinations |
US10316088B2 (en) | 2016-06-28 | 2019-06-11 | Xencor, Inc. | Heterodimeric antibodies that bind somatostatin receptor 2 |
US10870709B2 (en) | 2016-07-22 | 2020-12-22 | New York University | Specific murine and humanized monoclonal antibodies detecting pathology associated secondary structure changes in proteins and peptides |
WO2018038046A1 (ja) | 2016-08-22 | 2018-03-01 | 中外製薬株式会社 | ヒトgpc3ポリペプチドを発現する遺伝子改変非ヒト動物 |
US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
US20180064758A1 (en) * | 2016-09-05 | 2018-03-08 | Ucl Business Plc | Chimeric antigen receptor |
IL265274B2 (en) * | 2016-09-16 | 2023-11-01 | Bionomics Ltd | A combination of an antibody against LGR5 and an antibody that inhibits PD-1 for the treatment of tumors |
US10621236B2 (en) * | 2016-09-16 | 2020-04-14 | At&T Intellectual Property I, L.P. | Concept based querying of graph databases |
LT3515946T (lt) * | 2016-09-23 | 2022-08-10 | Regeneron Pharmaceuticals, Inc. | Anti-muc16 (mucin 16) antikūnai |
WO2018060301A1 (en) | 2016-09-30 | 2018-04-05 | F. Hoffmann-La Roche Ag | Bispecific antibodies against cd3 |
BR112019007288A2 (pt) | 2016-10-14 | 2019-07-09 | Xencor Inc | proteína heterodimérica biespecífica, composições de ácido nucleico e de vetor de expressão, vetor de expressão, célula hospedeira, e, métodos para produzir proteína heterodimérica biespecífica e para tratar câncer em um paciente |
CN109923128A (zh) * | 2016-11-15 | 2019-06-21 | 基因泰克公司 | 用于用抗cd20/抗cd3双特异性抗体进行治疗的给药 |
WO2018106945A1 (en) | 2016-12-07 | 2018-06-14 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
CA3039446A1 (en) | 2016-12-20 | 2018-06-28 | F. Hoffmann-La Roche Ag | Combination therapy of anti-cd20/anti-cd3 bispecific antibodies and 4-1bb (cd137) agonists |
CA3054289A1 (en) | 2017-02-21 | 2018-08-30 | Regeneron Pharmaceuticals, Inc. | Anti-pd-1 antibodies for treatment of lung cancer |
US11492399B2 (en) * | 2017-03-24 | 2022-11-08 | Zenyaku Kogyo Co., Ltd. | Anti-IgM/B cell surface antigen bispecific antibody |
EP3600416B1 (en) | 2017-03-30 | 2023-06-07 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
KR102329635B1 (ko) * | 2017-04-24 | 2021-11-22 | 재단법인 목암생명과학연구소 | Her3 및 cd3에 결합하는 이중특이적 항체 |
US20200123256A1 (en) * | 2017-05-02 | 2020-04-23 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
CN110881274A (zh) | 2017-05-02 | 2020-03-13 | 普罗塞纳生物科学有限公司 | 识别tau的抗体 |
KR20200053437A (ko) | 2017-05-08 | 2020-05-18 | 아디맵 엘엘씨 | 항-cd3-결합 도메인 및 이를 포함하는 항체, 및 이를 생성하고 사용하는 방법 |
EP3409322A1 (en) | 2017-06-01 | 2018-12-05 | F. Hoffmann-La Roche AG | Treatment method |
WO2018223004A1 (en) * | 2017-06-01 | 2018-12-06 | Xencor, Inc. | Bispecific antibodies that bind cd20 and cd3 |
JP2020521791A (ja) * | 2017-06-02 | 2020-07-27 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | がんの治療のためのii型抗cd20抗体及び抗cd20/cd30二重特異性抗体 |
CN111132733A (zh) | 2017-06-30 | 2020-05-08 | Xencor股份有限公司 | 含有IL-15/IL-15Rα和抗原结合结构域的靶向异源二聚体Fc融合蛋白 |
AU2018298884A1 (en) | 2017-07-14 | 2020-02-27 | Immatics Biotechnologies Gmbh | Improved dual specificity polypeptide molecule |
TWI820041B (zh) | 2017-09-21 | 2023-11-01 | 中國大陸商上海藥明生物技術有限公司 | 新型抗CD3ε抗體 |
ES2759622T3 (es) | 2017-10-02 | 2020-05-11 | Certest Biotec S L | Anticuerpos anti-Dps y dispositivos de prueba para la detección de bacterias del género Campylobacter |
KR101973060B1 (ko) | 2017-10-20 | 2019-04-26 | 주식회사 녹십자 | 항-cd3 항체 및 이를 포함하는 암 치료용 약학적 조성물 |
CA3078676A1 (en) | 2017-10-30 | 2019-05-09 | F. Hoffmann-La Roche Ag | Method for in vivo generation of multispecific antibodies from monospecific antibodies |
WO2019086395A1 (en) | 2017-11-01 | 2019-05-09 | F. Hoffmann-La Roche Ag | Trifab-contorsbody |
US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
JP2021502100A (ja) | 2017-11-08 | 2021-01-28 | ゼンコア インコーポレイテッド | 新規抗pd−1配列を用いた二重特異性および単一特異性抗体 |
EP3728302A1 (en) | 2017-12-19 | 2020-10-28 | Xencor, Inc. | Engineered il-2 fc fusion proteins |
KR102575787B1 (ko) | 2017-12-21 | 2023-09-08 | 에프. 호프만-라 로슈 아게 | Hla-a2/wt1에 결합하는 항체 |
JP7315244B2 (ja) | 2018-01-09 | 2023-07-26 | エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド | Clec12a発現癌を標的にするための組成物および方法 |
CA3088649A1 (en) * | 2018-01-16 | 2019-07-25 | Lakepharma, Inc. | Bispecific antibody that binds cd3 and another target |
CR20200391A (es) | 2018-02-08 | 2020-10-19 | Genentech Inc | Moléculas biespecíficas de unión al antígeno y métodos de uso |
CN110218256B (zh) * | 2018-03-02 | 2020-12-08 | 广西医科大学 | 抗CD3的纳米抗体CD3/Nb29及其制备方法与应用 |
CN110218253B (zh) * | 2018-03-02 | 2020-12-04 | 广西医科大学 | 抗CD3的纳米抗体CD3/Nb14及其制备方法与应用 |
US11203646B2 (en) | 2018-03-14 | 2021-12-21 | Novimmune Sa | Anti-CD3 epsilon antibodies and methods of use thereof |
CN110305217B (zh) * | 2018-03-27 | 2022-03-29 | 广州爱思迈生物医药科技有限公司 | 双特异性抗体及其应用 |
CN112469477A (zh) | 2018-04-04 | 2021-03-09 | Xencor股份有限公司 | 与成纤维细胞活化蛋白结合的异源二聚体抗体 |
PE20210652A1 (es) | 2018-04-13 | 2021-03-26 | Hoffmann La Roche | Moleculas de union a antigeno dirigidas a her2 que comprenden 4-1bbl |
KR20210010862A (ko) | 2018-04-18 | 2021-01-28 | 젠코어 인코포레이티드 | IL-15/IL-15Rα Fc-융합 단백질 및 PD-1 항원 결합 도메인을 함유하는 PD-1 표적화 이종이량체 융합 단백질 및 이의 용도 |
AU2019256529A1 (en) | 2018-04-18 | 2020-11-26 | Xencor, Inc. | TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and TIM-3 antigen binding domains |
CN112513085B (zh) | 2018-05-24 | 2024-06-18 | 詹森生物科技公司 | Psma结合剂及其用途 |
JP7530299B2 (ja) * | 2018-05-24 | 2024-08-07 | ヤンセン バイオテツク,インコーポレーテツド | 抗cd3抗体及びその使用 |
WO2019228406A1 (en) * | 2018-05-29 | 2019-12-05 | Wuxi Biologics (Shanghai) Co., Ltd. | A novel anti-cd3/anti-cd20 bispecific antibody |
MA52742A (fr) * | 2018-06-09 | 2021-04-14 | Boehringer Ingelheim Int | Anticorps bispécifiques dll3-cd3 |
WO2019246317A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease or condition in a tissue originating from the endoderm |
US20230041197A1 (en) | 2018-06-20 | 2023-02-09 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
DE202019005887U1 (de) | 2018-07-03 | 2023-06-14 | Marengo Therapeutics, Inc. | Anti-TCR-Antikörpermoleküle und Verwendungen davon |
TWI728400B (zh) * | 2018-07-26 | 2021-05-21 | 美商美國禮來大藥廠 | Cd226促效劑抗體 |
AU2019331024A1 (en) | 2018-08-31 | 2021-03-18 | Regeneron Pharmaceuticals, Inc. | Dosing strategy that mitigates cytokine release syndrome for CD3/C20 bispecific antibodies |
CN110872356B (zh) * | 2018-09-03 | 2023-06-13 | 广西慧宝源健康产业有限公司 | 双特异性抗体及其使用方法 |
AU2019340647A1 (en) | 2018-09-10 | 2021-03-11 | Genentech, Inc. | Systems and methods for affinity capillary electrophoresis |
US11573226B2 (en) | 2018-09-10 | 2023-02-07 | Genentech, Inc. | Systems and methods for affinity capillary electrophoresis |
CN113195523A (zh) | 2018-10-03 | 2021-07-30 | Xencor股份有限公司 | IL-12异源二聚体Fc融合蛋白 |
US20200109200A1 (en) | 2018-10-09 | 2020-04-09 | Genentech, Inc. | Methods and systems for determining synapse formation |
TW202021986A (zh) | 2018-10-11 | 2020-06-16 | 美商英伊布里克斯公司 | 5t4單域抗體及其治療性組合物 |
EP3864045A2 (en) | 2018-10-11 | 2021-08-18 | Inhibrx, Inc. | Dll3 single domain antibodies and therapeutic compositions thereof |
US11208485B2 (en) | 2018-10-11 | 2021-12-28 | Inhibrx, Inc. | PD-1 single domain antibodies and therapeutic compositions thereof |
CA3115082A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | B7h3 single domain antibodies and therapeutic compositions thereof |
CN109400710A (zh) * | 2018-11-02 | 2019-03-01 | 山西大医院(山西医学科学院) | 一种靶向kif20a阳性胰腺癌双特异性抗体及其制备方法和应用 |
JP2022505144A (ja) * | 2018-11-05 | 2022-01-14 | 中外製薬株式会社 | Her2 s310f特異的な抗原結合分子 |
WO2020106757A1 (en) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
JP2022514343A (ja) | 2018-12-21 | 2022-02-10 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | 腫瘍標的化アゴニストcd28抗原結合分子 |
GB201901305D0 (en) * | 2019-01-30 | 2019-03-20 | Immunocore Ltd | Specific binding molecules |
JP2022523946A (ja) | 2019-03-01 | 2022-04-27 | ゼンコア インコーポレイテッド | Enpp3およびcd3に結合するヘテロ二量体抗体 |
CA3131531A1 (en) | 2019-03-03 | 2020-09-10 | Prothena Biosciences Limited | Antibodies recognizing tau |
MA55296A (fr) | 2019-03-14 | 2022-03-23 | Hoffmann La Roche | Traitement du cancer avec des anticorps bispécifiques de her2xcd3 en combinaison avec un mab anti-her2 |
KR102239781B1 (ko) * | 2019-04-08 | 2021-04-13 | 주식회사 녹십자 | Gpnmb 및 cd3에 특이적으로 결합하는 이중특이적 항체 및 이의 용도 |
EP3725370A1 (en) | 2019-04-19 | 2020-10-21 | ImmunoBrain Checkpoint, Inc. | Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease |
EP3956022A1 (en) | 2019-04-19 | 2022-02-23 | Janssen Biotech, Inc. | Methods of treating prostate cancer with an anti- psma/cd3 antibody |
US11434291B2 (en) | 2019-05-14 | 2022-09-06 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
CA3141909A1 (en) * | 2019-06-07 | 2020-12-10 | Adimab, Llc | High affinity anti-cd3 antibodies, and methods for their generation and use |
JP2022537019A (ja) * | 2019-06-21 | 2022-08-23 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Psmaおよびcd3に結合する二重特異性抗原結合分子の4-1bb共刺激と組み合わせての使用 |
EP3998081A4 (en) | 2019-07-05 | 2023-07-12 | Ono Pharmaceutical Co., Ltd. | TREATMENT OF BLOOD CANCER WITH PD-1/CD3 DUAL SPECIFICITY PROTEIN |
DE102019121007A1 (de) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Antigenbindende Proteine, die spezifisch an MAGE-A binden |
TW202112364A (zh) * | 2019-08-16 | 2021-04-01 | 美商蜻蛉治療股份有限公司 | 投與替司他賽(tesetaxel)與cyp3a4誘導劑之糖皮質素之方法 |
TW202135860A (zh) * | 2019-12-10 | 2021-10-01 | 美商再生元醫藥公司 | 含有抗cd20x抗cd3雙特異性抗體之穩定調配物 |
IL293423A (en) | 2019-12-13 | 2022-07-01 | Genentech Inc | Anti-ly6g6d antibodies and methods of use |
WO2021119482A1 (en) | 2019-12-13 | 2021-06-17 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
US11976120B2 (en) * | 2020-06-01 | 2024-05-07 | Boehringer Ingelheim International Gmbh | Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use |
US10981996B1 (en) * | 2020-06-01 | 2021-04-20 | Abexxa Biologics, Inc. | Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use |
CN115698068A (zh) | 2020-06-02 | 2023-02-03 | 艾库斯生物科学有限公司 | 抗tigit抗体 |
CA3182445A1 (en) | 2020-06-11 | 2021-12-16 | Francisco Leon | Methods and compositions for preventing type 1 diabetes |
TWI811703B (zh) | 2020-06-19 | 2023-08-11 | 瑞士商赫孚孟拉羅股份公司 | 與cd3及cd19結合之抗體 |
CN111705084B (zh) * | 2020-08-18 | 2020-12-08 | 江苏集萃药康生物科技有限公司 | 一种稳定表达荧光素酶及人cd20敲除鼠cd20的小鼠b细胞淋巴瘤细胞系构建方法 |
AU2021329378A1 (en) | 2020-08-19 | 2023-03-23 | Xencor, Inc. | Anti-CD28 compositions |
MX2023002545A (es) | 2020-09-10 | 2023-03-14 | Genmab As | Anticuerpo biespecifico contra cumulo de diferenciacion 3 (cd3) y cumulo de diferenciacion 20 (cd20) en terapia de combinacion para el tratamiento de linfoma difuso de celulas b grandes. |
MX2023002546A (es) | 2020-09-10 | 2023-03-14 | Genmab As | Anticuerpos biespecificos contra cumulo de diferenciacion 3 (cd3) y contra cumulo de diferenciacion 20 (cd20) para tratar leucemia linfocitica cronica. |
CN116406293A (zh) | 2020-09-10 | 2023-07-07 | 健玛保 | 用于治疗滤泡性淋巴瘤的联合疗法中的针对cd3和cd20的双特异性抗体 |
MX2023002540A (es) | 2020-09-10 | 2023-03-14 | Genmab As | Anticuerpo biespecifico contra el cumulo de diferenciacion 3 (cd3) y el cumulo de diferenciacion 20 (cd20) en terapia combinada para el tratamiento del linfoma folicular. |
AU2021339006A1 (en) | 2020-09-10 | 2023-04-13 | Genmab A/S | Bispecific antibody against CD3 and CD20 in combination therapy for treating diffuse large B-cell lymphoma |
WO2022072762A1 (en) | 2020-10-02 | 2022-04-07 | Regeneron Pharmaceuticals, Inc. | Combination of antibodies for treating cancer with reduced cytokine release syndrome |
IL302217A (en) * | 2020-11-04 | 2023-06-01 | Genentech Inc | Dosage for treatment with bispecific anti-CD20/anti-CD3 antibodies and anti-CD79B drug antibody conjugates |
JP7402381B2 (ja) * | 2020-11-04 | 2023-12-20 | ジェネンテック, インコーポレイテッド | 抗cd20/抗cd3二重特異性抗体による処置のための投与 |
CA3201219A1 (en) | 2020-12-04 | 2022-06-09 | Mir Ali | Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof |
AU2022206061A1 (en) | 2021-01-06 | 2023-07-06 | F. Hoffmann-La Roche Ag | Combination therapy employing a pd1-lag3 bispecific antibody and a cd20 t cell bispecific antibody |
EP4284838A2 (en) | 2021-01-28 | 2023-12-06 | Janssen Biotech, Inc. | Psma binding proteins and uses thereof |
WO2022192403A1 (en) | 2021-03-09 | 2022-09-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cldn6 |
US11859012B2 (en) | 2021-03-10 | 2024-01-02 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and GPC3 |
GB2623199A (en) | 2021-04-08 | 2024-04-10 | Marengo Therapeutics Inc | Multifunctional molecules binding to TCR and uses thereof |
EP4330282A1 (en) | 2021-04-30 | 2024-03-06 | F. Hoffmann-La Roche AG | Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate |
TW202244059A (zh) | 2021-04-30 | 2022-11-16 | 瑞士商赫孚孟拉羅股份公司 | 用抗cd20/抗cd3雙特異性抗體進行治療之給藥 |
CA3217180A1 (en) * | 2021-05-06 | 2022-11-10 | Amgen Research (Munich) Gmbh | Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases |
WO2022263507A1 (en) | 2021-06-17 | 2022-12-22 | Boehringer Ingelheim International Gmbh | Novel tri-specific binding molecules |
CN115490770A (zh) * | 2021-06-17 | 2022-12-20 | 鸿运华宁(杭州)生物医药有限公司 | 一种能与人eta和人cd3结合的双特异性抗体及其应用 |
CN115558023A (zh) * | 2021-07-02 | 2023-01-03 | 安源医药科技(上海)有限公司 | 抗cd3抗体及其用途 |
CN117897407A (zh) * | 2021-08-27 | 2024-04-16 | 石药集团巨石生物制药有限公司 | 抗Nectin-4抗体、药物缀合物及其制备方法和用途 |
WO2023056391A1 (en) * | 2021-09-30 | 2023-04-06 | City Of Hope | Anti-cd3 antibodies and uses thereof |
CN118076387A (zh) * | 2021-10-08 | 2024-05-24 | 艾贝乐医药科技有限公司 | 靶向表达cdh17的肿瘤的多特异性抗体及其制备和使用方法 |
CA3236006A1 (en) * | 2021-11-16 | 2023-05-25 | Genentech, Inc. | Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab |
AU2022413444A1 (en) | 2021-12-14 | 2024-06-27 | Cdr-Life Ag | Dual mhc-targeting t cell engager |
US20230295310A1 (en) * | 2022-03-20 | 2023-09-21 | Abcellera Biologics Inc. | CD3 T-Cell Engagers and Methods of Use |
US20230414750A1 (en) | 2022-03-23 | 2023-12-28 | Hoffmann-La Roche Inc. | Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy |
TW202346337A (zh) | 2022-03-29 | 2023-12-01 | 美商恩格姆生物製藥公司 | Ilt3及cd3結合劑以及其使用方法 |
US11958906B2 (en) | 2022-04-13 | 2024-04-16 | Genentech, Inc. | Pharmaceutical compositions of mosunetuzumab and methods of use |
WO2023201299A1 (en) | 2022-04-13 | 2023-10-19 | Genentech, Inc. | Pharmaceutical compositions of therapeutic proteins and methods of use |
WO2023198727A1 (en) | 2022-04-13 | 2023-10-19 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use |
WO2023219613A1 (en) * | 2022-05-11 | 2023-11-16 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
TW202413431A (zh) * | 2022-05-12 | 2024-04-01 | 日商安斯泰來製藥股份有限公司 | 抗taa和cd3的多特異性抗體 |
WO2023240156A1 (en) | 2022-06-08 | 2023-12-14 | Tidal Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof |
WO2024020564A1 (en) | 2022-07-22 | 2024-01-25 | Genentech, Inc. | Anti-steap1 antigen-binding molecules and uses thereof |
WO2024086617A2 (en) * | 2022-10-18 | 2024-04-25 | Adimab, Llc | Ph-dependent anti-cd3 antibodies and methods relating thereto |
WO2024088987A1 (en) | 2022-10-26 | 2024-05-02 | F. Hoffmann-La Roche Ag | Combination therapy for the treatment of cancer |
WO2024094741A1 (en) | 2022-11-03 | 2024-05-10 | F. Hoffmann-La Roche Ag | Combination therapy with anti-cd19/anti-cd28 bispecific antibody |
WO2024104988A1 (en) | 2022-11-15 | 2024-05-23 | F. Hoffmann-La Roche Ag | Recombinant binding proteins with activatable effector domain |
WO2024108032A2 (en) * | 2022-11-18 | 2024-05-23 | Jn Biosciences Llc | Anti-cd3 antibodies |
WO2024112867A1 (en) | 2022-11-23 | 2024-05-30 | University Of Georgia Research Foundation, Inc. | Compositions and methods of use thereof for increasing immune responses |
WO2024155807A1 (en) | 2023-01-18 | 2024-07-25 | Genentech, Inc. | Multispecific antibodies and uses thereof |
Family Cites Families (214)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4675187A (en) | 1983-05-16 | 1987-06-23 | Bristol-Myers Company | BBM-1675, a new antibiotic complex |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
ATE102631T1 (de) | 1988-11-11 | 1994-03-15 | Medical Res Council | Klonierung von immunglobulin sequenzen aus den variabelen domaenen. |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
AU6290090A (en) | 1989-08-29 | 1991-04-08 | University Of Southampton | Bi-or trispecific (fab)3 or (fab)4 conjugates |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
CA2405246A1 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with alterred binding properties |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
JP4124480B2 (ja) * | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
ATE503496T1 (de) | 1992-02-06 | 2011-04-15 | Novartis Vaccines & Diagnostic | Biosynthetisches bindeprotein für tumormarker |
EP0714409A1 (en) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Antibodies |
WO1995009864A1 (fr) | 1993-10-01 | 1995-04-13 | Teikoku Hormone Mfg. Co., Ltd. | Nouveau derive peptidique |
US5798100A (en) | 1994-07-06 | 1998-08-25 | Immunomedics, Inc. | Multi-stage cascade boosting vaccine |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
ATE299938T1 (de) | 1997-05-02 | 2005-08-15 | Genentech Inc | Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen |
US20030073809A1 (en) | 1997-06-16 | 2003-04-17 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
CA2293829C (en) | 1997-06-24 | 2011-06-14 | Genentech, Inc. | Methods and compositions for galactosylated glycoproteins |
US6248564B1 (en) | 1997-08-29 | 2001-06-19 | Harvard University | Mutant MHC class I molecules |
DE69840412D1 (de) | 1997-10-31 | 2009-02-12 | Genentech Inc | Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen |
US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
AU760562B2 (en) | 1997-12-05 | 2003-05-15 | Scripps Research Institute, The | Humanization of murine antibody |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
DK1068241T3 (da) | 1998-04-02 | 2008-02-04 | Genentech Inc | Antistofvarianter og fragmenter deraf |
EP2261229A3 (en) | 1998-04-20 | 2011-03-23 | GlycArt Biotechnology AG | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
CN1689646A (zh) | 1998-08-11 | 2005-11-02 | 拜奥根Idec公司 | 包括施用抗-cd20抗体的b-细胞淋巴瘤联合疗法 |
KR101092132B1 (ko) | 1998-11-09 | 2011-12-12 | 바이오겐 아이덱 인크. | 키메라 항-cd20항체를 이용한 순환성 종양세포와 관련된 혈액학적 악성종양의 치료법 |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
BR0008758A (pt) | 1999-01-15 | 2001-12-04 | Genentech Inc | Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante |
ES2568899T3 (es) | 1999-04-09 | 2016-05-05 | Kyowa Hakko Kirin Co., Ltd. | Procedimiento para controlar la actividad de una molécula inmunofuncional |
AU7950400A (en) | 1999-10-19 | 2001-04-30 | Kyowa Hakko Kogyo Co. Ltd. | Process for producing polypeptide |
US7105149B1 (en) | 1999-11-29 | 2006-09-12 | The Trustees Of Columbia University In The City Of New York | Isolation of five novel genes coding for new Fc receptors-type melanoma involved in the pathogenesis of lymphoma/myeloma |
ES2591102T3 (es) | 1999-11-29 | 2016-11-24 | The Trustees Of Columbia University In The City Of New York | Aislamiento de cinco genes novedosos que codifican nuevos melanomas de tipo receptor de Fc implicados en la patogénesis del linfoma/melanoma |
CA2393869A1 (en) | 1999-12-15 | 2001-06-21 | Genetech,Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
US20040005561A1 (en) | 2000-03-01 | 2004-01-08 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
IL151853A0 (en) | 2000-04-11 | 2003-04-10 | Genentech Inc | Multivalent antibodies and uses therefor |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
EP3690043A1 (en) | 2000-10-06 | 2020-08-05 | Kyowa Kirin Co., Ltd. | Antibody composition-producing cell |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US20040018194A1 (en) | 2000-11-28 | 2004-01-29 | Francisco Joseph A. | Recombinant anti-CD30 antibodies and uses thereof |
DE60131456T2 (de) | 2000-11-30 | 2008-07-10 | Medarex, Inc., Milpitas | Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern |
TWI255272B (en) | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
CU23007A1 (es) | 2001-04-06 | 2004-12-17 | Ct De Inmunologia Molecular Ct De Inmunologia Mole | Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos |
US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
ATE440869T1 (de) | 2001-06-20 | 2009-09-15 | Fibron Ltd | Fgfr3 blockierende antikírper, verfahren zum screening darauf und verwendungen davon |
EP1423510A4 (en) | 2001-08-03 | 2005-06-01 | Glycart Biotechnology Ag | ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED CELL CYTOTOXICITY DEPENDENT OF ANTIBODIES |
KR101008758B1 (ko) | 2001-09-18 | 2011-01-14 | 제넨테크, 인크. | 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물 |
US7888478B2 (en) | 2002-09-11 | 2011-02-15 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
US7858330B2 (en) | 2001-10-19 | 2010-12-28 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
US20050226869A1 (en) | 2001-10-19 | 2005-10-13 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
US20030157108A1 (en) | 2001-10-25 | 2003-08-21 | Genentech, Inc. | Glycoprotein compositions |
JP2005511627A (ja) | 2001-11-20 | 2005-04-28 | シアトル ジェネティクス,インコーポレーテッド | 抗cd30抗体を使用する免疫学的疾患の治療 |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
US20040259150A1 (en) | 2002-04-09 | 2004-12-23 | Kyowa Hakko Kogyo Co., Ltd. | Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa |
ATE503829T1 (de) | 2002-04-09 | 2011-04-15 | Kyowa Hakko Kirin Co Ltd | Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins |
EP1502603A4 (en) | 2002-04-09 | 2006-12-13 | Kyowa Hakko Kogyo Kk | AN ANTIBODY COMPOSITION CONTAINING MEDICAMENT FOR PATIENTS WITH Fc gamma RIIIa POLYMORPHISM |
US20040110704A1 (en) | 2002-04-09 | 2004-06-10 | Kyowa Hakko Kogyo Co., Ltd. | Cells of which genome is modified |
US7691568B2 (en) | 2002-04-09 | 2010-04-06 | Kyowa Hakko Kirin Co., Ltd | Antibody composition-containing medicament |
CA2481837A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Production process for antibody composition |
US7435797B2 (en) | 2002-04-10 | 2008-10-14 | Genentech, Inc. | Anti-HER2 antibody variants |
JP4753578B2 (ja) | 2002-06-03 | 2011-08-24 | ジェネンテック, インコーポレイテッド | 合成抗体ファージライブラリー |
CA2494104A1 (en) | 2002-07-31 | 2004-04-22 | Seattle Genetics, Inc. | Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders |
EP1391213A1 (en) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
CN103833854B (zh) | 2002-12-16 | 2017-12-12 | 健泰科生物技术公司 | 免疫球蛋白变体及其用途 |
WO2004065416A2 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
CA2526402A1 (en) * | 2003-06-05 | 2005-01-20 | Genentech, Inc. | Blys antagonists and uses thereof |
CA2542046A1 (en) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Fused protein composition |
CA2542125A1 (en) | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing antibody composition by using rna inhibiting the function of .alpha.1,6-fucosyltransferase |
EA202091901A1 (ru) | 2003-11-05 | 2020-11-24 | Роше Гликарт Аг | АНТИТЕЛА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ АФФИННОСТЬЮ К СВЯЗЫВАНИЮ С Fc-РЕЦЕПТОРОМ И ЭФФЕКТОРНОЙ ФУНКЦИЕЙ |
US7498298B2 (en) | 2003-11-06 | 2009-03-03 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
WO2005053742A1 (ja) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | 抗体組成物を含有する医薬 |
CA2551813C (en) | 2003-12-24 | 2014-08-12 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
CA2556752C (en) | 2004-02-23 | 2016-02-02 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
GB0404187D0 (en) | 2004-02-25 | 2004-03-31 | Biotransformations Ltd | Binding agents |
JP5128935B2 (ja) | 2004-03-31 | 2013-01-23 | ジェネンテック, インコーポレイテッド | ヒト化抗TGF−β抗体 |
US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
EP2360186B1 (en) | 2004-04-13 | 2017-08-30 | F. Hoffmann-La Roche AG | Anti-P-selectin antibodies |
CA2567520A1 (en) | 2004-06-01 | 2005-12-15 | Genentech, Inc. | Maytansinoid-antibody conjugates |
TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
SI1791565T1 (sl) | 2004-09-23 | 2016-08-31 | Genentech, Inc. | Cisteinsko konstruirana protitelesa in konjugati |
US7999077B2 (en) | 2004-09-30 | 2011-08-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | IRTA2 antibodies and methods of use |
US20070134243A1 (en) | 2004-12-01 | 2007-06-14 | Gazzard Lewis J | Antibody drug conjugates and methods |
US7947839B2 (en) | 2004-12-01 | 2011-05-24 | Genentech, Inc. | Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use |
CN101103042A (zh) | 2005-01-12 | 2008-01-09 | 米德列斯公司 | Irta-2抗体及其用途 |
JP5620626B2 (ja) | 2005-03-31 | 2014-11-05 | 中外製薬株式会社 | 会合制御によるポリペプチド製造方法 |
EP1874821B1 (de) | 2005-04-26 | 2013-04-17 | Trion Pharma Gmbh | Kombination von antikörpern mit glukokortikoiden zur behandlung von krebs |
MX2007015010A (es) | 2005-06-02 | 2008-03-14 | Astrazeneca Ab | Anticuerpos dirigidos a cd20 y usos de los mismos. |
ES2373080T3 (es) | 2005-06-20 | 2012-01-31 | Genentech, Inc. | Anticuerpos que se unen al antígeno tat10772 asociado a tumores para el diagnóstico y tratamiento de un tumor. |
US8219149B2 (en) | 2005-06-29 | 2012-07-10 | Nokia Corporation | Mobile communication terminal |
BRPI0613361A2 (pt) * | 2005-07-01 | 2011-01-04 | Medarex Inc | anticorpo monoclonal humano isolado, composição, imunoconjugado, molécula biespecìfica, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, camundongo transgênico, método para modular uma resposta imune num indivìduo, método para inibir crescimento de células tumorais num indivìduo, método para tratar uma doença infecciosa num indivìduo, método para aumentar uma resposta imune a um antìgeno num indivìduo, método para tratar ou prevenir uma doença inflamatória num indivìduo e método para preparar o anticorpo anti-pd-l1 |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
CA2625440C (en) | 2005-10-11 | 2023-06-13 | Micromet Ag | Compositions comprising cross-species-specific antibodies and uses thereof |
EP1957531B1 (en) | 2005-11-07 | 2016-04-13 | Genentech, Inc. | Binding polypeptides with diversified and consensus vh/vl hypervariable sequences |
WO2007064919A2 (en) | 2005-12-02 | 2007-06-07 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
EP1820513A1 (en) | 2006-02-15 | 2007-08-22 | Trion Pharma Gmbh | Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies |
PL1999154T3 (pl) | 2006-03-24 | 2013-03-29 | Merck Patent Gmbh | Skonstruowane metodami inżynierii heterodimeryczne domeny białkowe |
EP2016101A2 (en) | 2006-05-09 | 2009-01-21 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
SG172698A1 (en) * | 2006-06-12 | 2011-07-28 | Trubion Pharmaceuticals Inc | Single-chain multivalent binding proteins with effector function |
US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
WO2008109533A2 (en) | 2007-03-02 | 2008-09-12 | Medarex, Inc. | Human antibodies that bind multiple irta family proteins, and uses thereof |
MX2009010611A (es) * | 2007-04-03 | 2010-03-26 | Micromet Ag | Enlazadores biespecificos, especificos para especies. |
RS52492B (en) | 2007-04-03 | 2013-02-28 | Amgen Research (Munich) Gmbh | MOLECULES WHICH INTERSPECIALLY SPECIFICALLY BISPECIFICALLY Bind |
RU2769948C2 (ru) | 2007-04-03 | 2022-04-11 | Эмджен Рисерч (Мьюник) Гмбх | CD3-Эпсилон-связывающий домен с межвидовой специфичностью |
ES2695047T3 (es) | 2007-04-03 | 2018-12-28 | Amgen Research (Munich) Gmbh | Dominio de unión específico entre especies |
CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
JP6035009B2 (ja) | 2007-08-22 | 2016-11-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用 |
JP5490714B2 (ja) | 2007-11-28 | 2014-05-14 | メディミューン,エルエルシー | タンパク質製剤 |
EP2235056A1 (en) | 2007-12-21 | 2010-10-06 | Genentech, Inc. | Crystallization of anti-cd20 antibodies |
EP2238169A1 (en) | 2007-12-26 | 2010-10-13 | Biotest AG | Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates |
EP2240495B1 (en) | 2008-02-01 | 2015-07-15 | Genentech, Inc. | Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods |
WO2009106096A1 (en) * | 2008-02-27 | 2009-09-03 | Fresenius Biotech Gmbh | Treatment of resistant tumors with trifunctional antibodies |
BRPI0910810A2 (pt) | 2008-07-15 | 2019-09-24 | Genentech Inc | conjugados derivados de antraciclina, veículo polimérico, anticorpo, peptídeo ou proteína, veículo t-[cho]m, composições farmacêuticas, métodos de tratamento do câncer ou de distúrbios da proliferação celular, derivado de antraciclina, composto conjugado droga-anticorpo, uso, artigo de manufatura e método de produção de um composto conjugado droga-anticorpo" |
US8895702B2 (en) | 2008-12-08 | 2014-11-25 | City Of Hope | Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies |
US20110178279A1 (en) | 2009-08-03 | 2011-07-21 | Williams John C | Development of masked therapeutic antibodies to limit off-target effects: application to anti-egfr antibodies |
US20100189727A1 (en) | 2008-12-08 | 2010-07-29 | Tegopharm Corporation | Masking Ligands For Reversible Inhibition Of Multivalent Compounds |
SG174992A1 (en) | 2009-04-01 | 2011-11-28 | Genentech Inc | Anti-fcrh5 antibodies and immunoconjugates and methods of use |
MX2011010265A (es) | 2009-04-01 | 2011-10-11 | Genentech Inc | Anticuerpos anti-fcrh5 e inmunoconjugados y metodos de uso. |
ES2708124T3 (es) * | 2009-04-27 | 2019-04-08 | Oncomed Pharm Inc | Procedimiento para preparar moléculas heteromultiméricas |
MY164121A (en) * | 2009-06-26 | 2017-11-30 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
EP2482212A4 (en) | 2009-09-25 | 2014-02-26 | Sh Nat Eng Res Ct Nanotech Co | METHOD FOR DETECTING HIGH AFFAIR PROTEINS WITH COMPUTER BASED DESIGN |
PT2519543T (pt) | 2009-12-29 | 2016-10-07 | Emergent Product Dev Seattle | Proteínas de ligação de heterodímero e suas utilizações |
US20130129723A1 (en) * | 2009-12-29 | 2013-05-23 | Emergent Product Development Seattle, Llc | Heterodimer Binding Proteins and Uses Thereof |
TWI653333B (zh) | 2010-04-01 | 2019-03-11 | 安進研究(慕尼黑)有限責任公司 | 跨物種專一性之PSMAxCD3雙專一性單鏈抗體 |
MA34277B1 (fr) | 2010-04-15 | 2013-06-01 | Spirogen Developments Sarl | Pyrrolobenzodiazépines et conjugués de celles-ci |
KR101930964B1 (ko) | 2010-04-20 | 2018-12-19 | 젠맵 에이/에스 | 이종이량체 항체 fc-함유 단백질 및 그의 생산 방법 |
WO2011143545A1 (en) * | 2010-05-14 | 2011-11-17 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
IL299365A (en) * | 2010-05-27 | 2023-02-01 | Genmab As | Monoclonal antibodies against 2HER |
CN103153339B (zh) | 2010-05-27 | 2021-05-04 | 根马布股份公司 | 针对her2表位的单克隆抗体 |
US9193791B2 (en) | 2010-08-03 | 2015-11-24 | City Of Hope | Development of masked therapeutic antibodies to limit off-target effects |
RU2013110876A (ru) | 2010-08-24 | 2014-09-27 | Рош Гликарт Аг | Активируемые биспецифические антитела |
US8962804B2 (en) | 2010-10-08 | 2015-02-24 | City Of Hope | Meditopes and meditope-binding antibodies and uses thereof |
EP2635607B1 (en) | 2010-11-05 | 2019-09-04 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the fc domain |
PL2637670T5 (pl) | 2010-11-10 | 2024-06-10 | Amgen Research (Munich) Gmbh | Zapobieganie działaniom niepożądanym spowodowanym przez domeny wiążące specyficzne względem CD3 |
BR112013013311A2 (pt) | 2010-11-30 | 2017-09-19 | Chugai Pharmaceutical Co Ltd | agente terapêutico de indução de citotoxicidade |
CA2818635C (en) | 2010-12-06 | 2021-06-15 | National Reseach Council Of Canada | Antibodies selective for cells presenting erbb2 at high density |
US10689447B2 (en) * | 2011-02-04 | 2020-06-23 | Genentech, Inc. | Fc variants and methods for their production |
AU2012222833B2 (en) | 2011-03-03 | 2017-03-16 | Zymeworks Inc. | Multivalent heteromultimer scaffold design and constructs |
IN2013MN01438A (ja) | 2011-03-17 | 2015-06-12 | Univ Ramot | |
EA028804B1 (ru) | 2011-03-25 | 2018-01-31 | Гленмарк Фармасьютикалс С.А. | Гетеродимерные иммуноглобулины |
CN103476795B (zh) | 2011-03-29 | 2016-07-06 | 罗切格利卡特公司 | 抗体Fc变体 |
AU2012245116A1 (en) | 2011-04-20 | 2013-11-07 | Genmab A/S | Bispecific antibodies against HER2 and CD3 |
US20140170148A1 (en) | 2011-04-20 | 2014-06-19 | Genmab A/S | Bispecific antibodies against her2 |
CN107903325B (zh) | 2011-05-16 | 2021-10-29 | 埃泰美德(香港)有限公司 | 多特异性fab融合蛋白及其使用方法 |
AU2012259161B2 (en) * | 2011-05-21 | 2017-04-06 | Macrogenics, Inc. | CD3-binding molecules capable of binding to human and non-human CD3 |
EP2578230A1 (en) | 2011-10-04 | 2013-04-10 | Trion Pharma Gmbh | Removal of Tumor Cells from Intraoperative Autologous Blood Salvage |
US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
JP6114902B2 (ja) * | 2011-12-27 | 2017-04-19 | ディヴェロップメント センター フォー バイオテクノロジー | 軽鎖架橋二重特異性抗体 |
GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
MX353382B (es) | 2012-03-01 | 2018-01-10 | Amgen Res Munich Gmbh | Moleculas de union polipeptido de larga duracion. |
EP2869845B1 (en) | 2012-07-06 | 2019-08-28 | Genmab B.V. | Dimeric protein with triple mutations |
WO2014022540A1 (en) | 2012-08-02 | 2014-02-06 | Regeneron Pharmaceuticals, Inc. | Multivalent antigen-binding proteins |
EP2885002A4 (en) | 2012-08-14 | 2016-04-20 | Ibc Pharmaceuticals Inc | BISPECIFIC ANTIBODIES REDIRECTED AGAINST T CELLS FOR THE TREATMENT OF DISEASES |
JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
CA2892059C (en) | 2012-11-21 | 2023-02-14 | Wuhan Yzy Biopharma Co., Ltd. | Bispecific antibody |
CA2889298C (en) | 2012-11-30 | 2024-01-02 | Anton Belousov | Identification of patients in need of pd-l1 inhibitor cotherapy |
US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
JO3529B1 (ar) | 2013-02-08 | 2020-07-05 | Amgen Res Munich Gmbh | مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد |
IL305629A (en) | 2013-02-15 | 2023-11-01 | Univ California | Chimeric antigen receptor and methods of using it |
WO2014153164A1 (en) | 2013-03-14 | 2014-09-25 | The California Institute For Biomedical Research | Targeting agent antibody conjugates and uses thereof |
US20140302037A1 (en) | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
BR112015023498A2 (pt) | 2013-03-15 | 2017-10-10 | Glaxosmithkline Ip No 2 Ltd | formulação para uma proteína terapêutica |
SG11201508231UA (en) | 2013-04-19 | 2015-11-27 | Covagen Ag | Novel bispecific binding molecules with antitumoral activity |
US10633453B2 (en) | 2013-05-28 | 2020-04-28 | Kaohsiung Medical University | Antibody locker for the inactivation of protein drug |
JP2016520600A (ja) | 2013-05-28 | 2016-07-14 | ヌマブ アクチェンゲゼルシャフト | 新規抗体 |
AR096687A1 (es) | 2013-06-24 | 2016-01-27 | Genentech Inc | Anticuerpos anti-fcrh5 |
US20160355588A1 (en) | 2013-07-12 | 2016-12-08 | Zymeworks Inc. | Bispecific CD3 and CD19 Antigen Binding Constructs |
ES2912932T3 (es) | 2013-07-25 | 2022-05-30 | Cytomx Therapeutics Inc | Anticuerpos multiespecíficos, anticuerpos activables multiespecíficos y procedimientos de uso de los mismos |
SG11201603244VA (en) | 2013-11-04 | 2016-05-30 | Glenmark Pharmaceuticals Sa | Production of t cell retargeting hetero-dimeric immunoglobulins |
JP6817064B2 (ja) | 2013-11-27 | 2021-01-20 | ザイムワークス,インコーポレイテッド | Her2を標的とする二重特異性抗原結合性コンストラクト |
NZ720515A (en) | 2013-12-17 | 2022-12-23 | Genentech Inc | Methods of treating cancers using pd-1 axis binding antagonists and taxanes |
CA3131724A1 (en) | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
TWI701042B (zh) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
KR102364383B1 (ko) | 2014-05-29 | 2022-02-17 | 마크로제닉스, 인크. | 삼중-특이적 결합 분자 및 그것의 사용 방법 |
US9611325B2 (en) | 2014-07-21 | 2017-04-04 | Wuhan Yzy Biopharma Co., Ltd. | Construction and application of bispecific antibody HER2xCD3 |
EP3172236B1 (en) | 2014-07-25 | 2020-09-30 | Memorial Sloan Kettering Cancer Center | Bispecific her2 and cd3 binding molecules |
JP7020909B2 (ja) | 2014-07-25 | 2022-02-16 | シトムクス セラピューティクス,インコーポレイティド | 抗-cd3抗体、活性化可能抗-cd3抗体、多重特異的抗-cd3抗体、多重特異的活性化可能抗-cd3抗体、及びそれらの使用方法 |
BR112016030462A2 (pt) | 2014-08-04 | 2018-01-16 | F. Hoffmann-La Roche Ag | moléculas de ligação, um ou mais polinucleotídeos isolados, um ou mais vetores, célula hospedeira, método de produção de uma molécula de ligação, composição farmacêutica, uso da molécula de ligação, método de tratamento de doenças e de indução da lise de células alvo |
WO2016019969A1 (en) | 2014-08-08 | 2016-02-11 | Ludwig-Maximilians-Universität München | Subcutaneously administered bispecific antibodies for use in the treatment of cancer |
WO2016036678A1 (en) | 2014-09-02 | 2016-03-10 | Medimmune, Llc | Formulations of bispecific antibodies |
MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
KR102614189B1 (ko) | 2014-11-17 | 2023-12-18 | 리제너론 파아마슈티컬스, 인크. | Cd3xcd20 이특이적 항체를 이용한 종양의 치료 방법 |
EA201790984A1 (ru) | 2014-12-05 | 2018-05-31 | Дженентек, Инк. | Анти-cd79b антитела и способы их применения |
MX2017008875A (es) | 2015-01-08 | 2017-09-27 | Genmab As | Anticuerpos biespecificos contra cd3 y cd20. |
MX2017010795A (es) | 2015-02-24 | 2018-04-11 | Bioatla Llc | Proteínas biológicas condicionalmente activas. |
WO2016135239A1 (en) | 2015-02-25 | 2016-09-01 | Biotecnol Limited | Fusion protein comprising three binding domains to her2 |
EP3778640A1 (en) | 2015-05-01 | 2021-02-17 | Genentech, Inc. | Masked anti-cd3 antibodies and methods of use |
MX2017015011A (es) | 2015-05-28 | 2018-03-23 | Genentech Inc | Ensayo a base de celulas para detectar homodimeros anti-cd3. |
US20160361360A1 (en) | 2015-06-12 | 2016-12-15 | Immunomedics, Inc. | Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs |
US10501545B2 (en) | 2015-06-16 | 2019-12-10 | Genentech, Inc. | Anti-CLL-1 antibodies and methods of use |
EP3310811B1 (en) | 2015-06-16 | 2021-06-16 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
AR105026A1 (es) | 2015-06-16 | 2017-08-30 | Genentech Inc | ANTICUERPOS MADURADOS POR AFINIDAD Y HUMANIZADOS PARA FcRH5 Y MÉTODOS PARA SU USO |
CA2986592A1 (en) | 2015-06-17 | 2016-12-22 | Genentech, Inc. | Anti-her2 antibodies and methods of use |
US10822419B2 (en) | 2015-06-26 | 2020-11-03 | University Of Southern California | Masking chimeric antigen receptor T cells for tumor-specific activation |
CA2997406C (en) | 2015-12-09 | 2024-05-28 | F. Hoffmann-La Roche Ag | Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies or cytokine release |
JP7438662B2 (ja) | 2016-01-25 | 2024-02-27 | ジェネンテック, インコーポレイテッド | T細胞依存性二重特異的抗体をアッセイするための方法 |
CN109923128A (zh) | 2016-11-15 | 2019-06-21 | 基因泰克公司 | 用于用抗cd20/抗cd3双特异性抗体进行治疗的给药 |
US10561686B2 (en) | 2018-01-12 | 2020-02-18 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expansion and uses thereof |
CA3088649A1 (en) | 2018-01-16 | 2019-07-25 | Lakepharma, Inc. | Bispecific antibody that binds cd3 and another target |
-
2014
- 2014-12-17 CA CA3131724A patent/CA3131724A1/en active Pending
- 2014-12-17 AU AU2014364805A patent/AU2014364805B2/en active Active
- 2014-12-17 EP EP24170644.9A patent/EP4410315A2/en active Pending
- 2014-12-17 KR KR1020227003049A patent/KR102433591B1/ko active IP Right Grant
- 2014-12-17 TW TW103144203A patent/TWI643873B/zh active
- 2014-12-17 SI SI201431638T patent/SI3192812T1/sl unknown
- 2014-12-17 CN CN202310133492.0A patent/CN116041529A/zh active Pending
- 2014-12-17 KR KR1020217006446A patent/KR102357961B1/ko active IP Right Grant
- 2014-12-17 IL IL263466A patent/IL263466B2/en unknown
- 2014-12-17 PL PL17156352T patent/PL3192812T3/pl unknown
- 2014-12-17 UA UAA201607113A patent/UA120753C2/uk unknown
- 2014-12-17 DK DK17156352.1T patent/DK3192812T3/da active
- 2014-12-17 ES ES17156352T patent/ES2813074T3/es active Active
- 2014-12-17 MX MX2016007958A patent/MX2016007958A/es active IP Right Grant
- 2014-12-17 DK DK14828608.1T patent/DK3083689T3/da active
- 2014-12-17 PL PL14828608T patent/PL3083689T3/pl unknown
- 2014-12-17 LT LTEP20170466.5T patent/LT3736292T/lt unknown
- 2014-12-17 FI FIEP20170466.5T patent/FI3736292T3/fi active
- 2014-12-17 WO PCT/US2014/070951 patent/WO2015095392A1/en active Application Filing
- 2014-12-17 PT PT171563521T patent/PT3192812T/pt unknown
- 2014-12-17 ES ES14828608T patent/ES2811923T3/es active Active
- 2014-12-17 SG SG10201809385RA patent/SG10201809385RA/en unknown
- 2014-12-17 PE PE2016000830A patent/PE20161217A1/es unknown
- 2014-12-17 BR BR122021025087-1A patent/BR122021025087B1/pt active IP Right Grant
- 2014-12-17 KR KR1020167019223A patent/KR102225489B1/ko active Protection Beyond IP Right Term
- 2014-12-17 CA CA2932288A patent/CA2932288C/en active Active
- 2014-12-17 KR KR1020237029926A patent/KR20230132612A/ko not_active Application Discontinuation
- 2014-12-17 KR KR1020227027967A patent/KR20220116581A/ko not_active Application Discontinuation
- 2014-12-17 EP EP14828608.1A patent/EP3083689B1/en active Active
- 2014-12-17 EP EP20170466.5A patent/EP3736292B1/en active Active
- 2014-12-17 CN CN202010636573.9A patent/CN112390883A/zh active Pending
- 2014-12-17 EP EP17156352.1A patent/EP3192812B1/en active Active
- 2014-12-17 MX MX2020001752A patent/MX2020001752A/es unknown
- 2014-12-17 PT PT148286081T patent/PT3083689T/pt unknown
- 2014-12-17 EA EA201691266A patent/EA038933B1/ru unknown
- 2014-12-17 IL IL302303A patent/IL302303A/en unknown
- 2014-12-17 PT PT201704665T patent/PT3736292T/pt unknown
- 2014-12-17 CN CN201480075726.XA patent/CN106029696B/zh active Active
- 2014-12-17 CA CA3055708A patent/CA3055708C/en active Active
- 2014-12-17 US US14/574,132 patent/US10174124B2/en active Active
- 2014-12-17 SI SI201431637T patent/SI3083689T1/sl unknown
- 2014-12-17 LT LTEP14828608.1T patent/LT3083689T/lt unknown
- 2014-12-17 RS RS20200773A patent/RS60443B1/sr unknown
- 2014-12-17 PE PE2020001924A patent/PE20210648A1/es unknown
- 2014-12-17 BR BR122021025085-5A patent/BR122021025085B1/pt active IP Right Grant
- 2014-12-17 RS RS20200791A patent/RS60453B1/sr unknown
- 2014-12-17 HU HUE14828608A patent/HUE050159T2/hu unknown
- 2014-12-17 DK DK20170466.5T patent/DK3736292T3/da active
- 2014-12-17 NZ NZ72130914A patent/NZ721309A/en unknown
- 2014-12-17 TW TW107134362A patent/TWI701261B/zh active
- 2014-12-17 JP JP2016539276A patent/JP6449295B2/ja active Active
- 2014-12-17 CR CR20160314A patent/CR20160314A/es unknown
- 2014-12-17 LT LTEP17156352.1T patent/LT3192812T/lt unknown
- 2014-12-17 TW TW109124003A patent/TWI747385B/zh active
- 2014-12-17 CN CN201910446481.1A patent/CN110156893B/zh active Active
- 2014-12-17 PE PE2020000702A patent/PE20210107A1/es unknown
- 2014-12-17 HU HUE17156352A patent/HUE050156T2/hu unknown
- 2014-12-17 SG SG11201604990PA patent/SG11201604990PA/en unknown
- 2014-12-17 BR BR112016014022-2A patent/BR112016014022B1/pt active IP Right Grant
- 2014-12-17 SG SG10201800250XA patent/SG10201800250XA/en unknown
-
2016
- 2016-05-31 IL IL245945A patent/IL245945B/en active IP Right Grant
- 2016-06-02 ZA ZA2016/03755A patent/ZA201603755B/en unknown
- 2016-06-17 PH PH12016501186A patent/PH12016501186A1/en unknown
- 2016-06-17 CL CL2016001556A patent/CL2016001556A1/es unknown
-
2017
- 2017-03-29 US US15/473,242 patent/US10640572B2/en active Active
- 2017-11-17 JP JP2017221759A patent/JP6526158B2/ja active Active
-
2018
- 2018-09-27 US US16/144,686 patent/US11186650B2/en active Active
- 2018-09-27 US US16/144,452 patent/US10865251B2/en active Active
-
2019
- 2019-03-11 JP JP2019044073A patent/JP6764968B2/ja active Active
-
2020
- 2020-01-07 AU AU2020200101A patent/AU2020200101B2/en active Active
- 2020-02-13 US US16/790,656 patent/US11732054B2/en active Active
- 2020-02-13 US US16/790,616 patent/US11530275B2/en active Active
- 2020-07-21 HR HRP20201143TT patent/HRP20201143T1/hr unknown
- 2020-07-22 HR HRP20201144TT patent/HRP20201144T1/hr unknown
- 2020-09-14 JP JP2020153481A patent/JP2021006042A/ja not_active Withdrawn
-
2022
- 2022-05-27 AU AU2022203605A patent/AU2022203605A1/en active Pending
- 2022-06-01 ZA ZA2022/06078A patent/ZA202206078B/en unknown
- 2022-06-20 JP JP2022098882A patent/JP7418501B2/ja active Active
- 2022-06-20 JP JP2022098883A patent/JP2022137074A/ja not_active Withdrawn
- 2022-08-22 NL NL301194C patent/NL301194I2/nl unknown
- 2022-09-01 HU HUS2200041C patent/HUS2200041I1/hu unknown
- 2022-09-06 US US17/930,018 patent/US20230002506A1/en active Pending
- 2022-09-22 LT LTPA2022519C patent/LTPA2022519I1/lt unknown
- 2022-09-26 FR FR22C1048C patent/FR22C1048I2/fr active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2017504314A5 (ja) | ||
HRP20201143T1 (hr) | Protutijela anti-cd3 i postupci uporabe | |
JP2018526972A5 (ja) | ||
JP7508425B2 (ja) | シグナル調節タンパク質αに対する抗体及び使用方法 | |
AU2015353416B2 (en) | Heterodimeric antibodies that bind CD3 and CD38 | |
CA3020864A1 (en) | Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof | |
JP2018527887A5 (ja) | ||
EP3668898B1 (en) | Humanized antibodies for cd3 | |
US11352432B2 (en) | Antibodies specifically binding to human IL-1R7 | |
RU2018114523A (ru) | Анти-tigit антитела и способы применения | |
HRP20191584T1 (hr) | Anti-cd79b protutijela i načini uporabe | |
JP2020503260A5 (ja) | ||
US20180305465A1 (en) | Heterodimeric antibodies that bind cd3 and cd38 | |
FI3310814T3 (fi) | HUMANISOITUJA JA AFFINITEETTIKYPSIÄ FcRH5-VASTA-AINEITA JA KÄYTTÖMENETELMIÄ | |
JP2018519263A5 (ja) | ||
US20220403037A1 (en) | Anti-ccr8 antibodies and uses thereof | |
AU2021221123A1 (en) | Anti-BCMA therapy in autoimmune disorders | |
TW202241956A (zh) | 新穎抗cd24抗體 | |
JPWO2022098648A5 (ja) |